Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has a stable fundamental performance, with progress in innovation and internationalization accelerating [1] - In 2025, the company reported revenue of 12.02 billion yuan (up 1.76% year-on-year) and a net profit attributable to shareholders of 2.023 billion yuan (down 1.84% year-on-year) [3][4] - The company maintains a gross margin of 65.90% (up 0.45 percentage points) and a net margin of 20.06% (up 0.55 percentage points) [3] - The company is optimistic about its innovation and internationalization strategies, although the promotion of new products like IL-17A/F will take time, leading to a downward revision of profit forecasts for 2026-2028 [4] Financial Performance - In 2025, the revenue breakdown by business segment includes: - Chemical preparations: 6.222 billion yuan (up 1.67%) - Traditional Chinese medicine: 1.674 billion yuan (up 18.81%) - Biopharmaceuticals: 201 million yuan (up 17.5%) [4] - The company expects net profits for 2026, 2027, and 2028 to be 2.125 billion yuan, 2.394 billion yuan, and 2.751 billion yuan respectively, with corresponding EPS of 2.39 yuan, 2.70 yuan, and 3.10 yuan [4] - The current stock price corresponds to a P/E ratio of 13.9, 12.4, and 10.8 for the years 2026, 2027, and 2028 respectively [4] Research and Development Progress - The company is advancing its differentiated innovation pipeline, with key products such as Aripiprazole microspheres approved for market in May 2025 and IL-17A/F expected to enter commercialization in 2026 [5] - The company is also expanding its local presence in Southeast Asia, having initiated the acquisition of Vietnamese listed company Imexpharm to leverage local resources for the development and commercialization of innovative and high-end generic drugs [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 6.272 billion yuan in H1 2025, a slight decrease of 0.17% year-on-year, while the net profit attributable to the parent company was 1.281 billion yuan, reflecting a growth of 9.40% year-on-year [4] - The company maintains a strong gross margin of 66.02% and a net profit margin of 24.73%, with significant improvements in net profit margin by 3.17 percentage points year-on-year [4] - The company is expected to continue its differentiated innovation strategy, with projected net profits of 2.276 billion yuan, 2.521 billion yuan, and 2.801 billion yuan for the years 2025, 2026, and 2027 respectively, leading to an EPS of 2.52 yuan, 2.79 yuan, and 3.10 yuan per share [4] Financial Performance Summary - In H1 2025, the company's sales expenses ratio was 27.69%, management expenses ratio was 4.77%, and R&D expenses ratio was 6.89% [4] - The company’s chemical preparations generated 3.270 billion yuan in revenue, with notable performance in digestive products (1.351 billion yuan, +3.87%) and psychiatric products (0.317 billion yuan, +6.89%) [5] - The company’s diversified product matrix is advancing rapidly, with several innovative drugs in the pipeline, including a long-acting formulation of Aripiprazole and a small nucleic acid drug targeting uric acid production [6] Financial Projections - The company is projected to have a revenue of 12.247 billion yuan in 2025, with a year-on-year growth of 3.7% [7] - The projected P/E ratios for 2025, 2026, and 2027 are 16.4, 14.8, and 13.3 respectively, indicating a favorable valuation trend [7]